Skip to main content
VCbacked
Log inGet Started

Kenai Therapeutics

San Diego, United States

Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.

$82.0M raised
Feb 2024
Series A
BiotechnologyHealth CareMedicalTherapeutics

Top Investors

The Column GroupCure VenturesAlaska Permanent FundCalifornia Institute for Regenerative MedicineSaisei Ventures

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Kenai Therapeutics

How much funding has Kenai Therapeutics raised?
Kenai Therapeutics has raised $82.0M in total funding. The most recent round was Series A. The last funding was announced in February 2024.
Who are Kenai Therapeutics's investors?
Kenai Therapeutics's investors include The Column Group, Cure Ventures, Alaska Permanent Fund, California Institute for Regenerative Medicine, Saisei Ventures.
Where is Kenai Therapeutics headquartered?
Kenai Therapeutics is headquartered in San Diego, United States.
What does Kenai Therapeutics do?
Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.
What stage is Kenai Therapeutics at?
Kenai Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Kenai Therapeutics — Funding & Investors." VCBacked, February 29, 2024, https://www.vcbacked.co/company/kenai-therapeutics. Accessed June 10, 2026.
APA
VCBacked. (2024). Kenai Therapeutics — Funding & Investors. Retrieved June 10, 2026, from https://www.vcbacked.co/company/kenai-therapeutics
Wikipedia (cite web)
{{cite web |title=Kenai Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kenai-therapeutics |website=VCBacked |access-date=June 10, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong